Table 2 Relationship of p53 expression with clinicopathological characteristics

From: Factors influencing p53 expression in ovarian cancer as a biomarker of clinical outcome in multicentre studies

 

UK patients

Dutch patients

 

Normal p53

Excessive p53

P -value a

Normal p53

Excessive p53

P -value a

Age (years)

 <58

71 (52.2%)

65 (47.8%)

0.709

50 (56.2%)

39 (43.8%)

0.383

 ⩾58

76 (50.0%)

76 (50.0%)

 

49 (49.5%)

50 (50.5%)

 

FIGO stage

 Stage I/II

30 (50.0%)

30 (50.0%)

0.856

29 (70.7%)

12 (29.3%)

0.006

 Stage III/IV

117 (51.3%)

111 (48.7%)

 

69 (47.3%)

77 (52.7%)

 

Tumour type

 Serous

74 (48.1%)

80 (51.9%)

0.273

48 (45.7%)

57 (54.3%)

0.040

 Non-serous

72 (54.5%)

68 (45.5%)

 

51 (61.4%)

32 (38.6%)

 

Differentiation grade

 Grade I

16 (84.2%)

3 (15.8%)

0.003

26 (92.9%)

2 (7.1%)

<0.001

 Grade II/III

112 (48.5%)

119 (51.5%)

 

64 (44.1%)

81 (55.9%)

 

Residual disease

 <2 cm

74 (52.9%)

66 (47.1%)

0.404

44 (67.7%)

21 (32.3%)

0.002

 ⩾2 cm

68 (47.9%)

74 (52.1%)

 

49 (44.5%)

61 (55.5%)

 

Response to chemotherapy

CR/PR

27 (41.5%)

58 (58.5%)

0.139

39 (70.9%)

42 (71.2%)

0.974

SD/PD

21 (56.8%)

16 (43.2%)

 

16 (29.1%)

17 (28.8%)

 
  1. CR=complete response; FIGO=International Federation of Gynaecology and Obstetrics; PD=progressive disease; PR=partial response; SD=stable disease.
  2. aP-values were calculated using χ2 or Fisher's exact test, where appropriate.
  3. Bold signifies P<0.05.
Back to article page